Status:
WITHDRAWN
Intradetrusor Triamcinolone Injection in the Management of Interstitial Cystitis/Bladder Pain Syndrome
Lead Sponsor:
The University of Texas Medical Branch, Galveston
Conditions:
Interstitial Cystitis
Bladder Pain Syndrome
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This initial pilot project aims to study the use of FDA-approved 40mg triamcinolone injections in the bladder for the management of interstitial cystitis with or without Hunner's lesions. Intradetruso...
Eligibility Criteria
Inclusion
- Patients must meet an appropriate diagnosis of IC from NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases)
- Patients must be female
- 18 years or older
- Have an official diagnosis of Interstitial Cystitis/Bladder Pain Syndrome
Exclusion
- Patients who do not meet NIDDK inclusion criteria for Interstitial Cystitis as described above will not me enrolled in the study
- The presence of urinary tract or sexually transmitted infection (may be included once existing infection is treated and cleared)
- Pregnant women
- Patients who have the inability to consent on their own behalf
- Prisoners
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05226832
Start Date
August 1 2022
End Date
March 1 2023
Last Update
January 26 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.